Clinical Trials
262 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Duke University
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
FLUBUTBI
Hackensack Meridian Health
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Emory University
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
5
Institut Curie
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Weill Medical College of Cornell University
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
UF-BMT-LDND-101
University of Florida
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
Blood Samples to Identify Biomarkers of Busulfan
Fred Hutchinson Cancer Center
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
M.D. Anderson Cancer Center
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
Mayo Clinic
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Columbia University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Weill Medical College of Cornell University
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia
University of Utah
PONS
GWT-TUD GmbH
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
COSMOS
Centre Hospitalier Universitaire de Saint Etienne
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University
DC Vaccination in CML
Charite University, Berlin, Germany
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
BMT CTN 0901
Medical College of Wisconsin
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
University of Michigan Rogel Cancer Center
Retrospective Evaluation of CML Patients in the National Compassionate Program
Gruppo Italiano Malattie EMatologiche dell'Adulto
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Roswell Park Cancer Institute
GVAX vs. Placebo for MDS/AML After Allo HSCT
Dana-Farber Cancer Institute